A first-in-human phase 1/1b study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors

被引：0
|
作者：
Schwartz, G. [1 ]
Adkins, D. [2 ]
Heist, R. [3 ]
Werner, T. [4 ]
Abbott, M. [1 ]
Barber, S. [2 ]
Slusarz, K. [3 ]
Agarwal, N. [4 ]
Neuteboom, S. [5 ]
Faltaos, D. [5 ]
Chen, I. [5 ]
Christensen, J. [6 ]
Chao, R. [5 ]
Bauer, T. [7 ]
机构：
[1] Columbia Univ, Div Hematol & Oncol, Med Ctr, New York, NY USA
[2] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[3] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA
[4] Huntsman Canc Inst, Div Oncol, Salt Lake City, UT USA
[5] Mirati Therapeut, Clin Sci, San Diego, CA USA
[6] Mirati Therapeut, Discovery & Translat Sci, San Diego, CA USA
[7] Tennessee Oncol PLLC, Oncol, Sarah Cannon Res Inst, Nashville, TN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30233-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [41] First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors
    Li, Xiaoyu
    Shen, Qi
    Shu, Pei
    Qin, Diyuan
    Tang, Jie
    Zheng, Li
    Li, Qiu
    Gong, Yi
    Hao, Xinbao
    Wang, Yongsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] CHIR-258: first-in-human phase 1 dose escalating trial of an oral, selectively targeted tyrosine kinase inhibitor in patients with solid tumors.
    Sarker, D
    Evans, J
    Judson, I
    Butzberger, P
    Marriott, C
    Morrison, R
    Vora, J
    Heise, C
    Hannah, A
    de Bono, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 202S - 202S
  • [43] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors
    Sommerhalder, David
    Hamilton, Erika P.
    Mukohara, Toru
    Yonemori, Kan
    Mita, Monica M.
    Yamashita, Toshinari
    Zheng, Jenny
    Liu, Li
    Maity, Arnab K.
    Mishra, Natasha Homji
    Bogg, Orlaith
    Li, Meng
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
    Lee S. Rosen
    Patricia LoRusso
    Wen Wee Ma
    Jonathan W. Goldman
    Amy Weise
    A. Dimitrios Colevas
    Alex Adjei
    Salim Yazji
    Angela Shen
    Stuart Johnston
    Hsin-Ju Hsieh
    Iris T. Chan
    Branimir I. Sikic
    Investigational New Drugs, 2016, 34 : 604 - 613
  • [45] First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pis) with advanced solid tumors.
    Kumar, Rajiv
    Mateo, Joaquin
    Smith, Alan D.
    Khan, Khurum Hayat
    Ruddle, Ruth
    Swales, Karen E.
    Decordova, Shaun
    Backholer, Zoe
    Jones, Paul
    Tran, Christine
    Seeramraddi, Satyanarayana
    McLeod, Robert
    Yap, Timothy Anthony
    Raynaud, Florence I.
    Garrett, Michelle D.
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Varga, A.
    Soria, J. C.
    Hollebecque, A.
    LoRusso, P.
    Vaishampayan, U.
    Okrah, K.
    Huang, S. M. A.
    Murray, E.
    Sanabria-Bohorquez, S.
    Tagen, M.
    Dokainish, H.
    Mueller, L.
    Burris, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
  • [47] A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Varga, Andrea
    Soria, Jean-Charles
    Hollebecque, Antoine
    LoRusso, Patricia
    Bendell, Johanna
    Huang, Shih-Min A.
    Wagle, Marie-Claire
    Okrah, Kwame
    Liu, Lichuan
    Murray, Elaine
    Sanabria-Bohorquez, Sandra M.
    Tagen, Michael
    Dokainish, Hatem
    Mueller, Lars
    Burris, Howard
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1229 - 1236
  • [48] A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Patel, Manish R.
    Yap, Timothy A.
    McEachern, Kristen
    Kuplast-Barr, Kristy
    Utley, Luke
    Cleary, Lisa
    Manyak, Erika
    Bozon, Viviana
    Parasuraman, Sudha
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
    Rosen, Lee S.
    LoRusso, Patricia
    Ma, Wen Wee
    Goldman, Jonathan W.
    Weise, Amy
    Colevas, A. Dimitrios
    Adjei, Alex
    Yazji, Salim
    Shen, Angela
    Johnston, Stuart
    Hsieh, Hsin-Ju
    Chan, Iris T.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (05) : 604 - 613
  • [50] Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
    Bahleda, R.
    Meric-Bernstam, F.
    Goyal, L.
    Tran, B.
    He, Y.
    Yamamiya, I
    Benhadji, K. A.
    Matos, I
    Arkenau, H-T
    ANNALS OF ONCOLOGY, 2020, 31 (10) : 1405 - 1412
12345